PMID- 36809944
OWN - NLM
STAT- MEDLINE
DCOM- 20230607
LR  - 20230624
IS  - 1873-5576 (Electronic)
IS  - 1568-0096 (Linking)
VI  - 23
IP  - 7
DP  - 2023
TI  - Polycaprolactone-based Nanocarriers Containing 5-fluorouracil as a Therapeutic 
      Guided Drug Delivery Approach for Enhancing Anticancer Activity.
PG  - 524-533
LID - 10.2174/1568009623666230210140212 [doi]
AB  - Nowadays, nano-platforms designed for drug delivery systems (DDSs) such as 
      polymers, liposomes, and micelles have been demonstrated to be clinically 
      efficient. The sustained drug release is one of the advantages of DDSs, 
      especially polymer-based nanoparticles. The formulation could enhance the drug's 
      durability, in which the biodegradable polymers are the most interesting building 
      blocks of DDSs. Nano-carriers could circumvent many issues by localized drug 
      delivery and release via certain internalization routes such as intracellular 
      endocytosis paths and increasing biocompatibility. Polymeric nanoparticles and 
      their nanocomposite are one of the most important classes of materials that can 
      be used for the assembly of nanocarriers that can form complex, conjugated and 
      encapsulated forms. The site-specific drug delivery may arise from the ability of 
      nanocarriers to pass through the biological barrier, their specific interactions 
      with receptors, and passive targeting. The better circulation, uptake, and 
      stability along with targeting attributes lead to lesser side effects and damage 
      to normal cells. Hence, in this review, the most recent achievements on 
      polycaprolactone-based or -modified nanoparticles in drug delivery systems (DDSs) 
      for 5-fluorouracil (5-FU) are presented.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Mohammadian, Samaneh
AU  - Mohammadian S
AD  - Department of Biology, Science and Research Branch, Islamic Azad University, 
      Tehran, Iran.
FAU - Khazaei, Majid
AU  - Khazaei M
AD  - Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
AD  - Basic Sciences Research Institute, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
FAU - Maghami, Parvaneh
AU  - Maghami P
AD  - Department of Biology, Science and Research Branch, Islamic Azad University, 
      Tehran, Iran.
FAU - Avan, Amir
AU  - Avan A
AD  - Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
AD  - Basic Sciences Research Institute, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
AD  - Medical Genetics Research Center, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
FAU - Rezaei, Majid
AU  - Rezaei M
AD  - Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
AD  - Department of Medical Biotechnology and Nanotechnology, School of Medicine, 
      Mashhad University of Medical Sciences, Mashhad, Iran.
AD  - Nanotechnology & Catalysis Research Centre, Institute of Postgraduate Studies, 
      University Malaya, Kuala Lumpur, 50603, Malaysia.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Curr Cancer Drug Targets
JT  - Current cancer drug targets
JID - 101094211
RN  - U3P01618RT (Fluorouracil)
RN  - 24980-41-4 (polycaprolactone)
RN  - 0 (Drug Carriers)
RN  - 0 (Polymers)
SB  - IM
MH  - Humans
MH  - *Fluorouracil
MH  - Drug Carriers
MH  - Drug Delivery Systems
MH  - Polymers
MH  - *Nanoparticles
OTO - NOTNLM
OT  - 5-fluorouracil
OT  - Polycaprolactone
OT  - cancer
OT  - drug delivery
OT  - drug release
OT  - polymeric nanoparticles
EDAT- 2023/02/23 06:00
MHDA- 2023/06/07 06:42
CRDT- 2023/02/22 14:17
PHST- 2022/04/27 00:00 [received]
PHST- 2022/10/26 00:00 [revised]
PHST- 2022/12/27 00:00 [accepted]
PHST- 2023/06/07 06:42 [medline]
PHST- 2023/02/23 06:00 [pubmed]
PHST- 2023/02/22 14:17 [entrez]
AID - CCDT-EPUB-129419 [pii]
AID - 10.2174/1568009623666230210140212 [doi]
PST - ppublish
SO  - Curr Cancer Drug Targets. 2023;23(7):524-533. doi: 
      10.2174/1568009623666230210140212.